Luminex Earns U.S. Funding for COVID-19/Flu/RSV Multi-Test

Luminex has been granted $11.3 million in funding from HHS’ Biomedical Advanced Research and Development Authority (BARDA) to support its efforts to develop and validate a multi-panel COVID-19 test.

The respiratory panel combines influenza A and B, respiratory syncytial virus (RSV) and SARS-CoV-2 targets to distinguish between the viruses and will deliver results in less than two hours, Luminex said. The company’s original SARS-CoV-2 assay was granted Emergency Use Authorization by the FDA last year and also received support from BARDA.

The test is being designed to run on Luminex’s ARIES real-time polymerase chain reaction (RT-PCR) automated molecular diagnostic platforms.